title: Phase II study of mitoxantrone for liver metastases from breast cancer.
abstract: Mitoxantrone was given to 19 patients with liver metastases from breast cancer and biochemical evidence of liver dysfunction. In all, 2 patients received the drug at a dose of 10 mg/m2 on days 1 and 2 of the first course of treatment; 1 patient was given 9 mg/m2 and 17 received 8 mg/m2. Subsequent courses were given at a dose of 10 mg/m2. Three patients (16%) showed a partial response, with time to progression of between 3 and 7 months. Toxicity was considerable, with myelosuppression being the major problem.
authors.affiliation: ICRF Clinical Oncology Unit, Guy's Hospital, London, U.K.
authors.forename: S M
authors.initials: SM
authors.lastname: O'Reilly
authors.forename: R E
authors.initials: RE
authors.lastname: Coleman
authors.forename: R D
authors.initials: RD
authors.lastname: Rubens
mesh_terms: D001853:Bone Marrow / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D003864:Depression, Chemical; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D008942:Mitoxantrone